more on the cancer drug i invented

@brainsurgerydropout

715.3K followers · usually 19.3K views a post

Views

1.7M

Likes

220.8K

Comments

4.4K

Shares

13.8K

SoundTikTok sound · Lofi

Promoted product

OS2966

OncoSynergy – Next generation immunotherapies

2 videos

Why it worked

The video leverages high-authority, personal storytelling by a founder-scientist, turning a complex medical topic into an accessible, serialized narrative that builds anticipation.

Summary

The creator explains the scientific nature and significance of a cancer drug candidate he invented called OS2966. He details its classification as a biologic and its unique role as a CD29 inhibitor in clinical trials.

Structure

1Introduction to the drug series
2Defining the drug as a biologic
3Explaining the target molecule
4Highlighting the clinical trial milestone
5Sharing the story behind the physical bottle

Original caption

Reply to @chicabonbon33 More info on the cancer drug candidate I invented: Pt 1! ✨🙏🏽✨ #MadScientistTiktok #stem #Science #medicine #glioblastoma 🧠

More from @brainsurgerydropout

Product placement

The creator holds a physical bottle of the drug candidate OS2966 throughout the video.

Call to action

Like and follow for part two.

On-screen text

more on the cancer drug i invented OS2966 OS2966 is not a pharmaceutical, it is a “biologic” Specifically, it is a monoclonal antibody OS2966 targets a molecule on cancer cells called CD29/beta1 integrin OS2966 is the world's first CD29 inhibitor to reach clinical trials This was a huge accomplishment for the team CD29 was thought to be “undruggable” mainly due to safety reasons That's why this bottle is special to me, it was bottle 7 used in our preclinical testing (warranting human trials) DISCLAIMER: OS2966 is an investigational drug and is not approved by FDA. Shawn Carbonell is cofounder, former CEO, and major shareholder of OncoSynergy, Inc., a private biotechnology company.

Transcript

Yo, due to popular demand, I'll be doing a three-part series on the cancer drug I invented called OS2966. Let's go. OS2966 is not a pharmaceutical, it is a biologic because it's produced in cells. Specifically, it is a monoclonal antibody. OS2966 targets a molecule on cancer cells called CD29/beta1 integrin. Now, OS2966 is the world's first CD29 inhibitor to reach clinical trials. This makes it first in class. This was a huge accomplishment for the team because CD29 was thought to be undruggable, mainly due to safety reasons. And that's why this bottle is special to me. It was bottle 7 used in our preclinical testing. We used the contents of this bottle to prove to FDA that we could target CD29 safely. Like and follow for part two.